Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 5,791 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: screening Clear all
Terminated Phase 4 Interventional

Comparison of Straumann BoneCeramic vs. Allograft Bone in Extraction Sockets

NCT00782236
View directory record Official record
Conditions
Tooth Loss
Interventions
Bone Graft Material
Device
Lead sponsor
Institut Straumann AG
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

NCT03961945
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Sponge Capsule
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
1,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Austin, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Coverage and Cost-of-Care (CC) Links- Financial Navigation Program

NCT05465577
View directory record Official record
Conditions
Financial Stress, Hematologic Cancer, Survivorship
Interventions
CC Links
Other
Lead sponsor
Jean Edward
Other
Eligibility
18 Years to 100 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 23, 2026, 2:07 AM EDT
Active, not recruiting Not applicable Interventional Results available

Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)

NCT01696981
View directory record Official record
Conditions
Colon Carcinoma, Rectal Carcinoma
Interventions
Screening Questionnaire Administration, Sigmoidoscopy
Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 74 Years
Enrollment
154,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care

NCT02377232
View directory record Official record
Conditions
Colon Cancer
Interventions
Decision Aid for Colon Cancer Screening, Usual Care Outreach for Colon Cancer Screening
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 75 Years
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional

VioOne HIV Profile Supplemental Assay

NCT03727932
View directory record Official record
Conditions
HIV Infections
Interventions
VioOne HIV Profile Supplemental Assay
Device
Lead sponsor
Avioq, Inc.
Industry
Eligibility
2 Years and older
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 23, 2026, 2:07 AM EDT
Active, not recruiting Phase 1 Interventional

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Enfortumab Vedotin, Erdafitinib, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Completed No phase listed Observational

VAlidation of a Lower Cost aneUploidy scrEen

NCT03087357
View directory record Official record
Conditions
Down Syndrome, Trisomy 18, Trisomy 13
Interventions
SmartNIPT
Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
2,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of Methadone Patient Access to Collaborative Treatment: a HEAL Initiative

NCT06513728
View directory record Official record
Conditions
Opioid Substitution Treatment Clinics, Patients, Staff
Interventions
MPACT Intervention
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 23, 2026, 2:07 AM EDT
Active, not recruiting Not applicable Interventional

Transferring Speed of Processing Gains to Everyday Cognitive Tasks After Stroke

NCT05162781
View directory record Official record
Conditions
Stroke, Cognitive Dysfunction
Interventions
Speed of Processing Training, Instrumental Activities of Daily Living In-lab Training, Cognitive Transfer Packagke, Family Caregiver Coaching, Follow-up Phone Calls, Healthy Lifestyle In-lab Training, Healthy Lifestyle Transfer Package
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study

NCT06535867
View directory record Official record
Conditions
Smoking, Smoking, Cigarette, Smoking, Tobacco, Betel Chewer's Mucosa, Tobacco Use, Tobacco Smoking, Alcohol Drinking, Smokeless Tobacco Hyperkeratosis
Interventions
mHealth
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

NCT04981509
View directory record Official record
Conditions
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Computed Tomography with Contrast, Erlotinib, Magnetic Resonance Imaging, Positron Emission Tomography, Sodium Fluoride F-18
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
La Jolla, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Recruiting Phase 1 Interventional

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06960395
View directory record Official record
Conditions
Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
Interventions
VIR-5525, Pembrolizumab
Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Scottsdale, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Active, not recruiting No phase listed Observational

NIOSH R21 WTC Asthma

NCT07222501
View directory record Official record
Conditions
Asthma
Interventions
SaMBA, Asthma Education - WTC Related
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Not listed No phase listed Observational

Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay

NCT05870592
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
bioAffinity Technologies Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

NCT05012098
View directory record Official record
Conditions
Olfactory Neuroblastoma, Esthesioneuroblastoma, Neoplasm of the Nasal Cavity
Interventions
Bintrafusp alfa/M7824, Ibuprofen, PET scan, CT scan, Tumor tissue biopsy, Brain MRI, Dotate scan, PET FDG scan, Nuclear bone scan, EKG
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 23, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Community-Based Screening for Chronic Kidney Disease

NCT07747363
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
outpatient clinic kidney-protective care
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

NCT06022822
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Placebo Administration, Urolithin A Supplement
Procedure · Drug · Dietary Supplement
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 2:07 AM EDT
Completed No phase listed Observational

Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening

NCT04746872
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Alinity m HR HPV
Diagnostic Test
Lead sponsor
Abbott Molecular
Industry
Eligibility
25 Years and older · Female only
Enrollment
14,935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 23, 2026, 2:07 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

NCT05515575
View directory record Official record
Conditions
Sarcoma,Soft Tissue, Sarcoma Uterus
Interventions
Niraparib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 2:07 AM EDT